A cancer therapy that prompts the body’s immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart’s largest blood vessels, a new study suggests.
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.
